BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv 2020;6:eaaz3221. [PMID: 32494639 DOI: 10.1126/sciadv.aaz3221] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Param NJ, Bramel ER, Sia D. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.006] [Reference Citation Analysis]
2 Jo J, Schiff D. Current Considerations in the Treatment of Grade 3 Gliomas. Curr Treat Options Oncol 2022. [PMID: 35913658 DOI: 10.1007/s11864-022-01000-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Maksoud S. The DNA Double-Strand Break Repair in Glioma: Molecular Players and Therapeutic Strategies. Mol Neurobiol 2022. [PMID: 35696013 DOI: 10.1007/s12035-022-02915-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Weng X, Song X, Shao R, Liu F, Liu Y. Aging and biliary tract cancers: Epidemiology, molecular biology, and clinical practice. Aging and Cancer 2022;3:95-104. [DOI: 10.1002/aac2.12054] [Reference Citation Analysis]
5 Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology 2022;75:1322-37. [PMID: 35226770 DOI: 10.1002/hep.32424] [Reference Citation Analysis]
6 Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022;11:1463. [DOI: 10.3390/cells11091463] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, Flavell RA, Prebet T, Bindra RS, Halene S. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia 2022. [PMID: 35273342 DOI: 10.1038/s41375-022-01536-x] [Reference Citation Analysis]
8 Persico P, Lorenzi E, Losurdo A, Dipasquale A, Di Muzio A, Navarria P, Pessina F, Politi LS, Lombardi G, Santoro A, Simonelli M. Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations. Cancers (Basel) 2022;14:1125. [PMID: 35267433 DOI: 10.3390/cancers14051125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
9 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gueble SE, Bindra RS. Oncometabolites as Regulators of DNA Damage Response and Repair. Semin Radiat Oncol 2022;32:82-94. [PMID: 34861999 DOI: 10.1016/j.semradonc.2021.09.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Aimar G, Paratore C, Zichi C, Marino D, Sperti E, Caglio A, Gamba T, De Vita F, Di Maio M. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step? Exploration of Targeted Anti-tumor Therapy 2021;2:448-64. [DOI: 10.37349/etat.2021.00056] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bonm A, Kesari S. DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies. Cancer J 2021;27:379-85. [PMID: 34570452 DOI: 10.1097/PPO.0000000000000540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C, Zhuang S, Li Y, Wang Y, Ai L, Liu Y, Liang H, Qi L, Gu Y. Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. Comput Struct Biotechnol J 2021;19:4435-46. [PMID: 34471490 DOI: 10.1016/j.csbj.2021.08.007] [Reference Citation Analysis]
15 Sears TK, Horbinski CM, Woolard KD. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat. J Neurooncol 2021;154:159-70. [PMID: 34424450 DOI: 10.1007/s11060-021-03829-0] [Reference Citation Analysis]
16 Xavier MA, Rezende F, Titze-de-Almeida R, Cornelissen B. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme. Biomolecules 2021;11:1188. [PMID: 34439854 DOI: 10.3390/biom11081188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Kayabolen A, Yilmaz E, Bagci-Onder T. IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications? Biomedicines 2021;9:799. [PMID: 34356864 DOI: 10.3390/biomedicines9070799] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
18 Qiu B, Kline C, Mueller S. Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. Front Oncol 2021;11:674596. [PMID: 34277419 DOI: 10.3389/fonc.2021.674596] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
19 Elmore KB, Schaff LR. DNA Repair Mechanisms and Therapeutic Targets in Glioma. Curr Oncol Rep 2021;23:87. [PMID: 34125307 DOI: 10.1007/s11912-021-01077-z] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
20 Garbarino J, Eckroate J, Sundaram RK, Jensen RB, Bindra RS. Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity. Transl Oncol 2021;14:101147. [PMID: 34118569 DOI: 10.1016/j.tranon.2021.101147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rominiyi O, Collis SJ. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. Mol Oncol 2021. [PMID: 34036721 DOI: 10.1002/1878-0261.13020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS. Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors. NAR Cancer 2021;3:zcab018. [PMID: 34027408 DOI: 10.1093/narcan/zcab018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
23 Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv 2021;3:vdab015. [PMID: 33738447 DOI: 10.1093/noajnl/vdab015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Li Z, Cai S, Li H, Gu J, Tian Y, Cao J, Yu D, Tang Z. Developing a lncRNA Signature to Predict the Radiotherapy Response of Lower-Grade Gliomas Using Co-expression and ceRNA Network Analysis. Front Oncol 2021;11:622880. [PMID: 33767991 DOI: 10.3389/fonc.2021.622880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
25 Chatwin HV, Cruz Cruz J, Green AL. Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy. FEBS J 2021;288:6127-41. [PMID: 33523591 DOI: 10.1111/febs.15739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
26 Pan YR, Wu CE, Yeh CN. ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner. Biomolecules 2020;10:E1529. [PMID: 33182492 DOI: 10.3390/biom10111529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
27 Xiao Y, Cui G, Ren X, Hao J, Zhang Y, Yang X, Wang Z, Zhu X, Wang H, Hao C, Duan H. A Novel Four-Gene Signature Associated With Immune Checkpoint for Predicting Prognosis in Lower-Grade Glioma. Front Oncol 2020;10:605737. [PMID: 33381460 DOI: 10.3389/fonc.2020.605737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Liu Y, Lang F, Chou FJ, Zaghloul KA, Yang C. Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. Biomedicines 2020;8:E294. [PMID: 32825279 DOI: 10.3390/biomedicines8090294] [Cited by in Crossref: 13] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
29 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
30 Savani MR, Abdullah KG, McBrayer SK. Amplifying the Noise: Oncometabolites Mask an Epigenetic Signal of DNA Damage. Mol Cell 2020;79:368-70. [PMID: 32763225 DOI: 10.1016/j.molcel.2020.07.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]